openPR Logo
Press release

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2025

12-20-2018 01:12 PM CET | Health & Medicine

Press release from: KuicK Research

Global Cancer Immunotherapy Market & Clinical Trials Outlook

“Global Cancer Immunotherapy Market & Clinical Trials Outlook 2025” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. According to report, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

For Report Sample Contact: neeraj@kuickresearch.com





Immunotherapy: Mending Cancer Regimens
1.1 Preface to Cancer Immunotherapy

1.2 Evolution of Cancer Immunotherapy



Categorization of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy

2.1.1 Cancer Vaccines

2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy

2.2.1 Adoptive Cell Transfer Immunotherapy

2.2.2 Immune Checkpoint Inhibitors



Fundamentals of Cancer Vaccines
3.1 Prologue of Cancer Vaccines

3.2 Cancer Vaccines in Immunotherapy

3.3 Commercial Aspects of Cancer Vaccines



New Era of Monoclonal Antibodies
4.1 Rudiments of Monoclonal Antibodies

4.2 Advents of Monoclonal Antibodies

4.3 Commercial Aspects of Monoclonal Antibodies



Trails of T-Cell Therapies
5.1 Adoptive Cell Transfer Technology

5.2 Strategies of Adoptive Cell Transfer

5.3 Commercial Aspects of Adoptive Cell Therapy



Aspects of Immune Checkpoint Inhibitors
6.1 Prelude to Immune Checkpoint Inhibitors

6.2 Implications of Immunecheck Point Inhibitors

6.3 Commercial Aspects of Immune Checkpoint Inhibitors





Immunomodulators in Cancer Immunotherapy
7.1 Perspective of Immunomodulators

7.2 Clinical Aspects of Immunomodulators

7.3 Commercial Aspects of Immunomodulators



Oncolytic Viral Immunotherapy
8.1 Concept to Oncolytic Viruses

8.2 Potential Approaches of Oncolytic Viruses

8.3 Commercial Aspects of Oncolytic Viruses



Cytokines in Cancer Immunotherapy
9.1 Fundamentals of Cytokines

9.2 Classification of Cytokines

9.3 Commercial Aspects of Cytokines



Interferons in Immunotherapy
10.1 Potentials of Interferons

10.2 Classification of Interferons

10.3 Clinical Applications of Interferons



Interleukins in Immunotherapy
11.1 Potentials of Interleukins

11.2 Clinical Applications of Interleukins



GM-CSF in Immunotherapy
12.1 Potentials of GM-CSF

12.2 Clinical Applications of GM-CSF



Global Economic Evaluations
13.1 Economic Aspects of Cancer Immunotherapy

13.2 Cancer Immunotherapy Cost by Product



Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends

14.2 Cancer Immunotherapy Pipeline Overview





Global Cancer Immunotherapy Market Dynamics
15.1 Favorable Market Parameters

15.2 Commercialization Challenges



Marketed Cancer Cell Therapies Drugs
16.1 Sipuleucel-T (Provenge®)

16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)



Marketed Cancer Cytokines Drugs
17.1 Aldesleukin (Proleukin®)

17.2 Denileukin Diftitox (ONTAK®)

17.3 Interferon Alpha (Multiferon®)

17.4 Interferon Alpha-2a (Roferon-A®)

17.5 Interferon Alpha-2a (Veldona®)

17.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)

17.7 Interferon Alpha-2b(Intron® A)

17.8 Interferon Alpha-2b Biosimilar(Bioferon™)

17.9 Interferon Alpha-2b Biosimilar (Intalfa®)

17.10 Interferon Alpha-2b Biosimilar

17.11 Interferon-Alpha-n3 (Alferon N®)

17.12 Interferon-Beta-1b (Feron®)

17.13 Interferon-Gamma (Ogamma®)

17.14 Interleukin-2 Biosimilar (Ilcass)

17.15 Teceleukin (Imunace™)



Marketed Cancer Vaccines
18.1 Bladder Cancer Vaccine (PACIS®)

18.2 Bladder Cancer Vaccine

18.3 BV NSCLC 001

18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)

18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)

18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

18.7 Melanoma Vaccine (MVax®)

18.8 Melanoma Vaccine (Melacine®)

18.9 Racotumomab (Vaxira®)

18.10 Sipuleucel-T (Provenge®)

18.11 Tertomotide (LucaVax)

18.12 Vitespen (Oncophage®)



Marketed Cancer Monoclonal Antibodies
19.1 Bevacizumab

19.2 Trastuzumab Emtansine

19.3 Trastuzumab Subcutaneous

19.4 Brentuximab Vedotin

19.5 Catumaxomab

19.6 Ipilimumab

19.7 Nivolumab

19.8 Pembrolizumab

19.9 Pertuzumab

19.10 Rituximab

19.11 Trastuzumab



Global Cancer Immunotherapy Market Future Prospects


Competitive Landscape
21.1 Abbvie

21.2 Advaxis

21.3 Altor BioScience

21.4 Amgen

21.5 Biogen Idec

21.6 Biogenomics

21.7 Celldex Therapeutics

21.8 Dendreon Corporation

21.9 Eli Lilly

21.10 Expression Genetics

21.11 Galena Biopharma

21.12 Genmab

21.13 Gilead Sciences

21.14 GlaxoSmithKline

21.15 ImmunoCellular Therapeutics

21.16 ImmunoGen

21.17 Inovio Pharmaceuticals

21.18 IRX Therapeutics

21.19 Merck

21.20 NeoStem Oncology

21.21 NewLink Genetics

21.22 Northwest Biotherapeutics

21.23 Novartis

21.24 Peregrine Pharmaceuticals

21.25 Pfizer

21.26 Philogen

21.27 Regulon

21.28 Roche

21.29 Seattle Genetics

21.30 ZymoGenetics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Immunotherapy Market & Clinical Trials Outlook 2025 here

News-ID: 1453451 • Views: 325

More Releases from KuicK Research

Stem Cell Therapy Revolutionizing Conventional Therapy Market
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Download Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportun …
"Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026" Report Highlights: Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 Cell Therapy Clinical Trial Insight by Indication, Company and Country Global Cell Therapy Clinical Pipeline: 767 Cell Therapies Globally Marketed Cell Therapies: 25 Cell Therapies Maximum Number of Marketed Cell Therapies In USA: 15 Therapies Price and Product Insight By Region/Country Regional Analysis of the Cell Therapy Market

All 5 Releases


More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and